When Roche pulled its cancer drug Lunsumio from Switzerland’s reimbursement list in July 2025, the decision sent a signal. Here was a pharmaceutical giant withdrawing a treatment from its home country, a wealthy nation with one of Europe’s strongest pharma sectors, because of pricing negotiations.
Switzerland isn’t alone in facing these pressures. Denmark recently lost access to Amgen’s cholesterol drug Repatha, and France heard Pfizer’s CEO warn that the company would “stop supplying France” rather than lower US prices to French levels.
Pharma pricing trends across Europe have shifted from gradual policy adjustments to fundamental restructuring of how and where companies launch new medicines.
This restructuring is creating a different kind of pharmaceutical industry, one that requires different expertise and roles than the sector employed five years ago.
Here’s everything you need to know:
The triple pressure reshaping European pharma
Three forces are converging to rewrite how pharmaceutical companies price, launch, and defend their products across Europe.
1. US MFN policy
The US now requires pharmaceutical companies to charge American consumers no more than the lowest prices offered to other wealthy countries.
This policy, known as Most Favoured Nation (MFN), targets reference countries that include Switzerland, Denmark, and other European markets that have historically negotiated lower drug prices than the US.
“It’s all about MFN—that’s the biggest pressure on Europe at the moment,” says headcount’s Managing Director Maurice Thornton. “The US has really put pressure on manufacturers. I never expected there would be such strong follow-through on election promises.”
Companies now face a choice: match European prices in the US (destroying their most profitable market) or withdraw products from European countries (protecting US revenue but abandoning entire markets). The data is yet to show which option they’re choosing.
Text
2. European value demonstration requirements
The US policy pushes from one direction, but European governments are tightening requirements from the other.
The EU launched a continent-wide Health Technology Assessment (HTA) in 2025, creating standardised processes for evaluating whether new drugs justify their cost.
Countries now demand evidence that treatments deliver meaningful clinical benefits before agreeing to pay, and several are experimenting with pay-for-performance contracts where reimbursement depends on whether the drug works in real-world use.
This creates a fundamental misunderstanding that colours public debate.
“People believe pharma companies are setting the prices,” Thornton explains, “but this is a massive process with governments, insurers, and other players.”
Manufacturers propose prices, but government agencies negotiate within budget constraints, considering comparative effectiveness data and political pressures that vary by country.
The result is a fragmented landscape where the same drug might launch at different prices—or not launch at all—depending on what each national health system will accept.
3. The Nordic collaboration model
Smaller European countries have responded by pooling their negotiating power.
Nordic nations now collaborate on pricing discussions, combining their markets to gain leverage that individual countries lack.
This approach creates efficiency for governments but adds another layer of complexity for pharmaceutical companies trying to navigate European launches.
A pricing decision that works for Sweden might not satisfy Finland, and companies must balance these competing demands.
What these pricing trends mean for pharma careers in Europe
These pricing pressures are actively changing which roles pharma companies need and what skills command premium salaries.
Growing role categories
Four specialisations are becoming increasingly more important:
- Market access and pricing strategists model how pricing decisions in one country cascade through international reference systems, determining launch sequences that protect global revenue.
- Health economics and outcomes research (HEOR) professionals design evidence frameworks that satisfy regulators, payers, and finance teams for products ranging from standard therapies to pay-for-performance gene therapy contracts.
- Regulatory affairs specialists navigate joint clinical assessments across EU member states, understanding how different countries weigh clinical endpoints, budget impact, and comparative effectiveness data.
- Government affairs and policy experts handle direct engagement with pricing authorities and HTA bodies, translating between clinical evidence and political constraints.
Learn more about pharmaceutical automation and how it’s shaping the market, too.
What does this mean for employers?
Competition for market access talent has intensified as every pharmaceutical company recognises the strategic importance of pricing expertise.
Attracting these professionals requires offering cross-functional exposure, multi-country scope, and demonstrable strategic impact.
What does this mean for job seekers?
The professionals gaining leverage understand both the technical and political dimensions of pharmaceutical pricing, with certifications from organisations like ISPOR providing foundational credentials.
Most valuable are professionals who understand regulatory and pricing frameworks on both sides of the Atlantic, as MFN policy has made US-Europe pricing dynamics inseparable.
The wild card of gene therapy
One-off curative treatments are breaking traditional pricing models.
A gene therapy that cures a disease with a single dose creates obvious value but unclear payment structures—should health systems pay €2 million upfront or spread costs across years based on whether patients stay disease-free?
This uncertainty is creating new roles:
- Pay-for-performance contracts require professionals who can design outcomes tracking infrastructure and coordinate long-term patient monitoring
- Annuity payment models need finance specialists who understand pharmaceutical risk profiles alongside healthcare budgeting cycles
- Real-world evidence generation has shifted from a post-approval afterthought to a permanent commercial function
European countries are testing different approaches.
Italy has implemented success-based pricing schemes, Germany continues evolving its AMNOG system to accommodate novel therapies, and several smaller nations are experimenting with managed entry agreements.
Switzerland's strategic position
Switzerland remains a strategic hub for pharmaceutical careers despite—and partly because of—pricing pressures.
Basel hosts the headquarters of Roche and Novartis, which means strategic decision-making on pricing and market access happens here even as clinical trials and manufacturing shift to other regions.
The Swiss government faces competing pressures:
- It can’t afford to let Switzerland become a primary reference point for US MFN pricing
- But it also can’t alienate employers that represent significant portions of the national economy
- This tension creates demand for professionals who understand both pharmaceutical industry economics and the Swiss political economy
Other European pharma hubs face similar dynamics.
Copenhagen, Dublin, and Brussels all host significant pharmaceutical operations as their governments navigate pricing negotiations that affect both national budgets and employment.
Navigating the new reality in 2026 and beyond
Pricing pressures are real, and some drugs will launch in Europe more slowly than they would have five years ago. But this complexity also creates opportunities for specialised professionals.
For employers, the market access and HEOR talent you hire now will determine your European commercial success over the next decade.
For job seekers, the professionals who can prove value will build careers in an industry under permanent pricing pressure but with no shortage of problems that need solving.
